Yale Catriona — SEC Form 4 filings
SEC reporting owner CIK 1779308. 30 Form 4 filings on record with FilingPulse; latest filed 2025-12-09.
Transaction summary — filings shown
Covers all 30 filings on record, filed 2024-03-06 to 2025-12-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 45 legs across 26 filings — 293,076 shares, $12,672,497 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 76.
- Largest priced transaction: sale of 27,340 shares @ $57.02 ($1,559,036) in Akero Therapeutics, Inc., filed 2025-01-31.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | 30 | — | 45 legs · 293,076 sh · $12,672,497 | 76 |
Form 4 filings — Yale Catriona
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-12-09 | 4 | Akero Therapeutics, Inc. (AKRO) | Disposition to issuer (D): 27,227 · Disposition to issuer (D): 47,573 · Disposition to issuer (D): 3,421 (derivative) · Disposition to issuer (D): 5,032 (derivative) · Disposition to issuer (D): 2,328 (derivative) · Disposition to issuer (D): 70,279 (derivative) · +5 more | EDGAR |
| 2025-11-06 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 3,527 @ $28.35 · Option exercise (M): 4,739 @ $21.10 · Option exercise (M): 3,527 (derivative) @ $0 · Option exercise (M): 4,739 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 659 @ $43.02 | EDGAR |
| 2025-07-18 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 10,000 @ $19.87 · Sale (S): 8,658 @ $52.87 · Sale (S): 1,342 @ $53.47 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 890 @ $23.87 | EDGAR |
| 2025-06-20 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 10,000 @ $21.10 · Sale (S): 6,210 @ $53.78 · Sale (S): 2,895 @ $54.80 · Sale (S): 895 @ $55.52 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 1,633 @ $54.84 | EDGAR |
| 2025-06-12 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 2,803 @ $54.00 | EDGAR |
| 2025-05-19 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 10,000 @ $21.10 · Sale (S): 2,837 @ $38.20 · Sale (S): 2,779 @ $39.46 · Sale (S): 4,384 @ $39.91 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 9,073 @ $21.10 · Sale (S): 7,873 @ $37.80 · Sale (S): 1,200 @ $38.62 · Option exercise (M): 9,073 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 10,000 @ $21.10 · Sale (S): 8,201 @ $44.70 · Sale (S): 1,799 @ $45.05 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 614 @ $44.88 | EDGAR |
| 2025-02-21 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 10,000 @ $21.10 · Sale (S): 9,100 @ $49.79 · Sale (S): 900 @ $50.63 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 49,074 @ $21.10 · Sale (S): 25,907 @ $55.15 · Sale (S): 14,467 @ $55.95 · Sale (S): 8,700 @ $57.01 · Option exercise (M): 20,000 (derivative) @ $0 · Option exercise (M): 20,000 (derivative) @ $0 · +1 more | EDGAR |
| 2025-01-31 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 16,849 @ $0.61 · Option exercise (M): 15,172 @ $6.36 · Option exercise (M): 21,569 @ $21.09 · Sale (S): 17,000 @ $55.16 · Sale (S): 9,250 @ $55.95 · Sale (S): 27,340 @ $57.02 · +4 more | EDGAR |
| 2024-12-18 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 24,300 @ $0 · Option exercise (M): 9,074 @ $21.10 · Sale (S): 9,074 @ $29.11 · Option exercise (M): 9,074 (derivative) @ $0 · Grant/award (A): 73,700 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 2,810 @ $30.79 | EDGAR |
| 2024-11-19 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 9,061 @ $21.10 · Sale (S): 8,761 @ $27.69 · Sale (S): 300 @ $28.82 · Option exercise (M): 9,061 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 10,000 @ $0.61 · Sale (S): 10,000 @ $35.19 · Option exercise (M): 8,890 (derivative) @ $0 · Option exercise (M): 1,110 (derivative) @ $0 | EDGAR |
| 2024-11-01 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 4,515 @ $21.10 · Sale (S): 4,515 @ $32.53 · Option exercise (M): 15,485 @ $21.10 · Sale (S): 15,485 @ $32.62 · Option exercise (M): 4,515 (derivative) @ $0 · Option exercise (M): 15,485 (derivative) @ $0 | EDGAR |
| 2024-10-16 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 14,825 @ $0.61 · Sale (S): 14,525 @ $30.50 · Sale (S): 300 @ $30.93 · Option exercise (M): 5,000 @ $0.61 · Sale (S): 6,136 @ $30.03 · Option exercise (M): 4,825 (derivative) @ $0 · +2 more | EDGAR |
| 2024-09-23 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 5,500 @ $0.61 · Sale (S): 5,500 @ $27.65 · Option exercise (M): 5,500 (derivative) @ $0 | EDGAR |
| 2024-09-18 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 2,485 @ $0.61 · Sale (S): 2,485 @ $27.52 · Option exercise (M): 2,037 @ $0.61 · Sale (S): 2,037 @ $27.55 · Option exercise (M): 3,871 @ $0.61 · Sale (S): 3,871 @ $27.56 · +3 more | EDGAR |
| 2024-09-13 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 637 @ $26.18 | EDGAR |
| 2024-09-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 949 @ $0.61 · Sale (S): 949 @ $27.61 · Option exercise (M): 949 (derivative) @ $0 | EDGAR |
| 2024-08-28 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 8,851 @ $0.61 · Sale (S): 8,851 @ $27.53 · Option exercise (M): 5,200 @ $0.61 · Sale (S): 5,200 @ $27.51 · Option exercise (M): 8,851 (derivative) @ $0 · Option exercise (M): 5,200 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 1,064 @ $19.94 | EDGAR |
| 2024-06-13 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 2,825 @ $22.64 | EDGAR |
| 2024-03-15 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 723 @ $28.33 | EDGAR |
| 2024-03-06 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 10,000 @ $6.36 · Option exercise (M): 10,646 @ $21.09 · Sale (S): 20,646 @ $35.49 · Option exercise (M): 10,000 (derivative) @ $0 · Option exercise (M): 10,646 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1779308 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →